Genetic modification of endothelial cells

US5674722A · kind A · utility

Assignees

• Somatix Therapy Corporation · US
• Whitehead Institute For Biomedical Research · US
• The Brigham and Women's Hospital, Inc. · US
• Howard Hughes Medical Institute · US
• New England Medical Center Hospitals. Inc. · US

Inventors

• Richard C. Mulligan · Cambridge, US
• Lawrence K. Cohen · Oakland, US
• Lori F. Rafield · Mill Valley, US
• Louis K. Birinyi · Boston, US
• Allan D. Callow · Chesterfield, US
• James M. Wilson · Glen Mills, US

Key dates

• Filing date: May 25, 1994
• Grant date: Oct 7, 1997
• Expiry date: May 25, 2014

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S623/921
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.